- Home
- HUT vs KNSA Comparison
HUT vs KNSA Comparison
Compare HUT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HUT | KNSA |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.7B |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HUT | KNSA |
|---|---|---|
| Price | $58.05 | $96.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 23 | 7 |
| Target Price | ★ $128.04 | $109.43 |
| AVG Volume (30 Days) | ★ 6.3M | 943.8K |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 1.14 |
| Revenue | $235,118,000.00 | ★ $677,564,000.00 |
| Revenue This Year | $26.10 | $54.96 |
| Revenue Next Year | $92.70 | $24.16 |
| P/E Ratio | ★ N/A | $84.26 |
| Revenue Growth | 44.79 | ★ 60.09 |
| 52 Week Low | $31.67 | $37.02 |
| 52 Week High | $140.80 | $99.31 |
Technical Indicators
Market Signals| Indicator | HUT | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 42.72 | 59.87 |
| Support Level | $44.25 | $72.76 |
| Resistance Level | $59.35 | $98.48 |
| Average True Range (ATR) | 6.12 | 5.13 |
| MACD | 1.07 | 0.28 |
| Stochastic Oscillator | 55.01 | 80.18 |
Price Performance
Historical ComparisonAbout HUT Hut 8 Corp.
Hut 8 Corp is an energy infrastructure platform that integrates power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.